Home » Stocks » BNTC

Benitec Biopharma Inc. (BNTC)

Stock Price: $3.96 USD 0.21 (5.60%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $3.93 -0.03 (-0.76%) Feb 24, 7:25 PM
Market Cap 18.89M
Revenue (ttm) 48,000
Net Income (ttm) n/a
Shares Out 4.30M
EPS (ttm) -5.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $3.96
Previous Close $3.75
Change ($) 0.21
Change (%) 5.60%
Day's Open 3.84
Day's Range 3.70 - 4.27
Day's Volume 915,630
52-Week Range 2.52 - 17.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

HAYWARD, Calif., Dec. 7, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December ...

PRNewsWire - 4 months ago

HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing no...

PRNewsWire - 4 months ago

HAYWARD, Calif., Oct. 2, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing no...

PRNewsWire - 5 months ago

HAYWARD, Calif., Sept. 23, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing ...

PRNewsWire - 5 months ago

HAYWARD, Calif., Sept. 1, 2020 /PRNewswire/ -- Benitec Biopharma, Inc.

PRNewsWire - 7 months ago

HAYWARD, Calif., July 8, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...

Investopedia - 11 months ago

Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.

Other stocks mentioned: SUPV, TRIB

About BNTC

Benitec Biopharma, a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.

Industry
Biotechnology
Founded
1995
CEO
Dr. Jerel A. Banks Ph.D., M.D.
Employees
14
Stock Exchange
NASDAQ
Ticker Symbol
BNTC
Full Company Profile

Financial Performance

Financial numbers in millions AUD.
Financial Statements